MDGL
Madrigal Pharmaceuticals Inc
$
489.260
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
494.550
Open
488.030
VWAP
486.10
Vol
294.19K
Mkt Cap
11.11B
Low
476.610
Amount
143.00M
EV/EBITDA(TTM)
--
Total Shares
21.31M
EV
10.33B
EV/OCF(TTM)
--
P/S(TTM)
14.63
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
372.88M
+75.22%
1.622
-185.35%
319.81M
+133.01%
0.172
-105.17%
309.76M
+199.81%
-0.725
-73.25%
Estimates Revision
The market is revising Upward the revenue expectations for Madrigal Pharmaceuticals, Inc. (MDGL) for FY2025, with the revenue forecasts being adjusted by 0.24% over the past three months. During the same period, the stock price has changed by 41.52%.
Revenue Estimates for FY2025
Revise Upward
+0.24%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+1.77%
In Past 3 Month
Stock Price
Go Up
+41.52%
In Past 3 Month
16 Analyst Rating
3.51% Upside
Wall Street analysts forecast MDGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDGL is 506.43 USD with a low forecast of 266.00 USD and a high forecast of 590.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Buy
1 Hold
1 Sell
Strong Buy
3.51% Upside
Current: 489.260
Low
266.00
Averages
506.43
High
590.00
3.51% Upside
Current: 489.260
Low
266.00
Averages
506.43
High
590.00
Citizens JMP
Outperform
maintain
$485 -> $527
2025-11-05
New
Reason
Citizens JMP
Price Target
$485 -> $527
2025-11-05
New
maintain
Outperform
Reason
Citizens JMP raised the firm's price target on Madrigal Pharmaceuticals to $527 from $485 and keeps an Outperform rating on the shares. Rezdiffra sales of $287M beat consensus estimates, driven by robust demand, with more than 29,500 patients now on the therapy in the U.S., the analyst tells investors in a research note. The firm is looking forward to Madrigal's presence and MASH leadership at the Liver Meeting, which is kicking off later this week, where Rezdiffra will be featured in numerous presentations covering efficacy, safety, real-world use, quality of life improvements, early biomarkers, and durability of fibrosis regression.
Clear Street
Buy
maintain
$431 -> $533
2025-11-04
New
Reason
Clear Street
Price Target
$431 -> $533
2025-11-04
New
maintain
Buy
Reason
Clear Street raised the firm's price target on Madrigal Pharmaceuticals to $533 from $431 and keeps a Buy rating on the shares to reflect Rezdiffra's continued strong performance, even as Wegovy enters the F2-F3 MASH market. As a result of Rezdiffra's sustained growth, the firm has increased its peak penetration assumption to 20% from 15% for F2-F3 MASH, the analyst noted.
Cantor Fitzgerald
Neutral -> Overweight
upgrade
2025-11-04
New
Reason
Cantor Fitzgerald
Price Target
2025-11-04
New
upgrade
Neutral -> Overweight
Reason
Cantor Fitzgerald upgraded Madrigal Pharmaceuticals to Overweight from Neutral.
Cantor Fitzgerald
Prakhar Agrawal
Neutral -> Overweight
upgrade
2025-11-04
New
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
2025-11-04
New
upgrade
Neutral -> Overweight
Reason
Cantor Fitzgerald analyst Prakhar Agrawal upgraded Madrigal Pharmaceuticals to Overweight from Neutral. The company reported another strong quarter for Rezdiffra, which outperformed high investor expectations, the analyst tells investors in a research note. Cantor says that with better clarity on Madrigal's 2026 growth and "no major near-term headwinds for the stock," it is less concerned about the company's valuation. It believes Madrigal see profitability in 2026.
BofA
Underperform
to
Neutral
upgrade
$266 -> $445
2025-11-03
New
Reason
BofA
Price Target
$266 -> $445
2025-11-03
New
upgrade
Underperform
to
Neutral
Reason
BofA upgraded Madrigal Pharmaceuticals to Neutral from Underperform with a price target of $445, up from $266.
BofA
Underperform -> Neutral
upgrade
$266 -> $445
2025-11-03
New
Reason
BofA
Price Target
$266 -> $445
2025-11-03
New
upgrade
Underperform -> Neutral
Reason
As previously reported, BofA upgraded Madrigal Pharmaceuticals to Neutral from Underperform with a price target of $445, up from $266. MASH treatment Rezdiffra has outperformed the firm's "initial cautious expectations," but the structural issues prompting its concerns remain, the analyst tells investors. With Rezdiffra's near-term uptake likely to continue, shares should retain a measure of support, but the firm thinks upside potential may be limited with competitive challenges increasing, the analyst added.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Madrigal Pharmaceuticals Inc (MDGL.O) is 182.65, compared to its 5-year average forward P/E of -18.00. For a more detailed relative valuation and DCF analysis to assess Madrigal Pharmaceuticals Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-18.00
Current PE
182.65
Overvalued PE
21.55
Undervalued PE
-57.56
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-10.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
3.08
Undervalued EV/EBITDA
-23.44
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
50.82
Current PS
488.58
Overvalued PS
155.55
Undervalued PS
-53.91
Financials
Annual
Quarterly
FY2025Q3
YoY :
+362.03%
287.27M
Total Revenue
FY2025Q3
YoY :
-2.00%
-113.98M
Operating Profit
FY2025Q3
YoY :
+6.76%
-114.19M
Net Income after Tax
FY2025Q3
YoY :
+3.25%
-5.08
EPS - Diluted
FY2025Q3
YoY :
-212.15%
75.99M
Free Cash Flow
FY2025Q3
YoY :
-2.95%
93.69
Gross Profit Margin - %
FY2025Q3
YoY :
-96.10%
-22.23
FCF Margin - %
FY2025Q3
YoY :
-76.89%
-39.75
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 147.47% over the last month.
Sold
0-3
Months
11.3M
USD
2
3-6
Months
109.5M
USD
14
6-9
Months
11.4M
USD
7
0-12
Months
15.6M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
3
61.9M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 176.46% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
6.8K
Volume
1
0-12
Months
35.0
Volume
1
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
5
209.8K
Volume
Months
0-12
2
75.9K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 147.47% over the last month.
Sold
0-3
Months
11.3M
USD
2
3-6
Months
109.5M
USD
14
6-9
Months
11.4M
USD
7
0-12
Months
15.6M
USD
11
Bought
0-3
0
0.0
USD
Months
3-6
3
61.9M
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MDGL News & Events
Events Timeline
2025-11-04 (ET)
2025-11-04
07:05:31
Madrigal Pharmaceuticals announces Q3 EPS of $5.08, up from $4.92 a year ago.
2025-08-20 (ET)
2025-08-20
05:43:00
Citizens JMP Increases Madrigal Pharmaceuticals Price Target to $485 from $483
2025-08-19 (ET)
2025-08-19
16:15:12
Madrigal Receives Conditional Marketing Approval for Rezdiffra from the European Commission
Sign Up For More Events
Sign Up For More Events
News
8.0
11-04NASDAQ.COMSignificant Options Activity on Tuesday: MDGL, HOG, SRPT
6.5
11-03MarketWatchBiotech Makes a Comeback: Reasons to Add These Rising Stocks to Your Portfolio Today.
4.0
11-03SeekingAlphaMadrigal Pharmaceuticals Receives Upgrade from BofA Due to Rezdiffra Adoption
Sign Up For More News
People Also Watch
CELH
Celsius Holdings Inc
41.520
USD
-7.86%
BMI
Badger Meter Inc
187.870
USD
+0.61%
BBIO
BridgeBio Pharma Inc
61.800
USD
-1.48%
EAT
Brinker International Inc
102.640
USD
+0.34%
ZK
ZEEKR Intelligent Technology Holding Ltd
27.570
USD
-1.18%
ESI
Element Solutions Inc
27.660
USD
+3.32%
FAF
First American Financial Corp
62.370
USD
+2.55%
AMKR
Amkor Technology Inc
34.780
USD
-1.05%
GNTX
Gentex Corp
23.480
USD
+1.82%
LNTH
Lantheus Holdings Inc
51.070
USD
-4.88%
FAQ
What is Madrigal Pharmaceuticals Inc (MDGL) stock price today?
The current price of MDGL is 489.26 USD — it has increased 0.14 % in the last trading day.
What is Madrigal Pharmaceuticals Inc (MDGL)'s business?
What is the price predicton of MDGL Stock?
What is Madrigal Pharmaceuticals Inc (MDGL)'s revenue for the last quarter?
What is Madrigal Pharmaceuticals Inc (MDGL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Madrigal Pharmaceuticals Inc (MDGL)'s fundamentals?
How many employees does Madrigal Pharmaceuticals Inc (MDGL). have?